

**Format for Disclosure of Related Party Transactions (applicable only for half-yearly filings i.e., 2nd and 4th quarter)**

Amount in (Lakhs)

												Additional disclosure of related party transactions - applicable only in case the related party transaction relates to loans, inter-corporate deposits, advances or investments made or given by the listed entity/ subsidiary. These details need to be disclosed only once, during the reporting period when such transaction was undertaken.											
Sr. No.	Details of the party (listed entity / subsidiary) entering into the transaction		Details of the counterparty		Type of related party transaction	Details of other related party transaction	Value of the related party transaction as approved by the audit committee	Remarks on approval by audit committee	Value of the related party transaction ratified by the audit committee	Date of Audit Committee Meeting where the ratification was approved	Value of transaction during the reporting period	In case monies are due to either party as a result of the transaction		In case any financial indebtedness is incurred to make or give loans, inter-corporate deposits, advances or investments				Details of the loans, inter-corporate deposits, advances or investments					
	Name	Name	Relationship of the counterparty with the listed entity or its subsidiary	Relationship of the counterparty with the listed entity or its subsidiary								Opening balance	Closing balance	Nature of indebtedness (loan/ issuance of debt/ any other etc.)	Details of other indebtedness	Cost	Tenure	Nature (loan/ advance/ intercorporate deposit/ investment)	Interest Rate (%)	Tenure	Secured/ unsecured	Purpose for which the funds will be utilised by the ultimate recipient of funds (endusage)	Notes
1	IND-SWIFT LABORATORIES LIMITED	ESSIX BIOSCIENCES LIMITED	OTHER RP	Investment			50,000.00	As approved by Board/ Shareholders				0.00	662.31	2,896.32									Textual Information(1)
2	IND-SWIFT LABORATORIES LIMITED	ESSIX BIOSCIENCES LIMITED	OTHER RP	Sale of goods or services			15,000.00	15000				3.72	0.00	0.00									Textual Information(2)
3	IND-SWIFT LABORATORIES LIMITED	ESSIX BIOSCIENCES LIMITED	OTHER RP	Purchase of goods or services			15,000.00	15000				287.92	0.00	284.46									Textual Information(3)
4	IND-SWIFT LABORATORIES LIMITED	SISLAX PHARMA PRIVATE LIMITED	OTHER RP	Any other transaction	Receipt of Services/ Creditors		1,000.00	1000				195.69	(20.40)	12.60									Textual Information(4)
5	IND-SWIFT LABORATORIES LIMITED	MOHALI GREEN ENVIRONMENT PRIVATE LIMITED	OTHER RP	Advance			500.00	500				22.00	0.00	22.00									Textual Information(5)
6	IND-SWIFT LABORATORIES LIMITED	MOHALI GREEN ENVIRONMENT PRIVATE LIMITED	OTHER RP	Investment			5,000.00	5000				0.00	3.00	3.00									Textual Information(6)
7	IND-SWIFT LABORATORIES LIMITED	IND-SWIFT LABORATORIES INC, USA	WHOLLY OWNED SUBSIDIARY	Sale of goods or services			Being a wholly owned subsidiary, there is no requirement					763.89	656.83	181.92									Textual Information(7)
8	IND-SWIFT LABORATORIES LIMITED	IND-SWIFT LABORATORIES INC, USA	WHOLLY OWNED SUBSIDIARY	Investment			Being a wholly owned subsidiary, there is no requirement					0.00	544.10	544.10									Textual Information(8)
9	IND-SWIFT LABORATORIES LIMITED	FORTUNE (INDIA) CONSTRUCTIONS LIMITED	WHOLLY OWNED SUBSIDIARY	Investment			Being a wholly owned subsidiary, there is no requirement					0.00	7,248.40	7,248.40									Textual Information(9)
10	IND-SWIFT LABORATORIES LIMITED	NAVRATTAN MUNJAL	promoter	Remuneration			As approved by NRC/ Board					235.64	0.00	0.00									Textual Information(10)
11	IND-SWIFT LABORATORIES LIMITED	HIMANSHU JAIN	promoter	Remuneration			As approved by NRC/ Board					176.13	0.00	37.40									Textual Information(11)
12	IND-SWIFT LABORATORIES LIMITED	RISHAV MEHTA	promoter	Remuneration			As approved by NRC/ Board					94.12	0.00	23.46									Textual Information(12)
13	IND-SWIFT LABORATORIES LIMITED	SAHIL MUNJAL	promoter	Remuneration			As approved by NRC/ Board					107.93	0.00	38.16									Textual Information(13)

**Total value of transaction during the reporting period** 2,517.18